Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
June 21st 2021
Immutep secures commitments for A$60 million through a two-tranche institutional placement to expand its clinical development and manufacturing program into late-stage settings
June 21st 2021
Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy
June 8th 2021
Immutep Reveals a New anti-LAG-3 Research Program
June 4th 2021
Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021
June 4th 2021
Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021
June 2nd 2021
Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor
June 1st 2021
Immutep Enters into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti
May 26th 2021
Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
May 25th 2021
Immutep to Present at the Jefferies Virtual Healthcare Conference
May 7th 2021
Immutep Operational Update
April 29th 2021
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
April 19th 2021
Immutep Quarterly Activities Report & Appendix 4C
April 16th 2021
Immutep Receives A$1,155,055 R&D Tax Incentive
April 8th 2021
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
April 7th 2021
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
March 16th 2021
Immutep Enters Second Collaboration with MSD for a New Randomised Phase IIB Trial in Head and Neck Cancer
March 9th 2021
Immutep Secures Second United States Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
March 5th 2021
Immutep Expands Part B of TACTI-002 Collaboration Trial
January 27th 2021
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study
January 22nd 2021
Immutep Quarterly Activities Report & Appendix 4C
January 22nd 2021
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
January 7th 2021
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
December 30th 2020
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
December 16th 2020
Immutep Upscales Efti Manufacturing
December 15th 2020
Immutep Operational Update
December 10th 2020
Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study
December 10th 2020
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
November 19th 2020
Immutep Announces Expansion of TACTI-002 Collaboration Trial
November 19th 2020
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development
November 10th 2020
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
November 9th 2020
Immutep Announces Australian Patent Grant for IMP701 Antibody
November 3rd 2020
Immutep’s TACTI-002 Data To Be Presented At Society For Immunotherapy Of Cancer 2020 Annual Meeting
October 27th 2020
Immutep AGM 2020 - Results of Meeting
October 27th 2020
Immutep AGM 2020 - Chairman's Address
October 27th 2020
Immutep AGM 2020 - CEO Marc Voigt's Presentation
October 23rd 2020
Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients
October 22nd 2020
Immutep Activities Report and Appendix 4C
October 21st 2020
Immutep Granted European Patent for IMP761
October 19th 2020
Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020
September 18th 2020
Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study
September 18th 2020
Immutep Reports Improving Results from INSIGHT-004 Trial
August 31st 2020
Immutep and Monash University Receive Grant Funding for LAG-3 Project
August 26th 2020
New Data From Immutep’s Efti To Be Presented At ESMO
August 18th 2020
Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study
August 11th 2020
Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
July 23rd 2020
Immutep Quarterly Activities Report & Appendix 4C
July 15th 2020
Immutep Announces United States Patent Grant for IMP701 Antibody
June 29th 2020
Immutep Completes Recruitment for Part A Of Phase II TACTI-002 Study
June 22nd 2020
Immutep Receives A$1,437,826 R&D Tax Incentive
June 1st 2020
Immutep Announces Improving Data from the Phase II TACTI-002 Study
June 1st 2020
Immutep Reports First Results from INSIGHT-004 Study
May 29th 2020
Immutep Receives A$3.6 Million R&D Tax Incentive from French Government
May 27th 2020
Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting
May 7th 2020
Immutep Granted Japanese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
May 1st 2020
Immutep to Present at Virtual Healthcare Investor Conference
April 30th 2020
Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting
April 29th 2020
Immutep Completes a A$12 Million Placement to Drive Development of its Immuno-Oncology and Autoimmune Asset Pipeline
April 28th 2020
Immutep Reports Positive Phase II TACTI-002 Data
April 27th 2020
IMM - Trading Halt
April 22nd 2020
Enrollment completed for the INSIGHT-004 Study
April 20th 2020
Immutep Quarterly Activities Report & Appendix 4C
April 16th 2020
Immutep Advances Cell Line Development for IMP761
April 14th 2020
Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020
April 8th 2020
Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer
March 25th 2020
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
March 20th 2020
Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti
March 9th 2020
Immutep Receives Second IND Approval for Efti from US FDA
February 19th 2020
Immutep Reports Positive TACTI-002 Data
February 4th 2020
Immutep to Present TACTI-002 Interim Data at German Cancer Congress
January 29th 2020
Immutep Activities Report
January 8th 2020
Immutep Expands Part C of TACTI-002 due to Positive Data
December 18th 2019
INSIGHT-004 Clinical Trial Update
November 13th 2019
Immutep Announces European Patent Grant for LAG525 Antibody
November 7th 2019
Immutep Presents Positive Interim Data from Phase II TACTI-002 Trial at SITC
November 1st 2019
IMMUTEP AGM 2019 - Chairman's Address
November 1st 2019
IMMUTEP AGM 2019 - CEO Marc Voigt's CEO Presentation
November 1st 2019
Update - Consolidation Split - IMM
October 28th 2019
Operational Update
October 15th 2019
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
October 10th 2019
Immutep Announces Data Presentations at Upcoming Industry Conferences
October 10th 2019
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
September 26th 2019
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
September 23rd 2019
Immutep to Receive £4M Milestone Payment from GSK
September 17th 2019
Immutep Announces Japanese Patent Grant for LAG525 Antibody
August 22nd 2019
Immutep Granted European Patent for Eftilagimod Alpha in Cancer
August 6th 2019
Immutep Completes A$6M Entitlement Offer
July 29th 2019
Operational Update
June 25th 2019
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
June 21st 2019
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
June 13th 2019
Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial
June 6th 2019
INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
June 3rd 2019
Immutep Presentation at ASCO 2019
May 23rd 2019
Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy
May 17th 2019
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
May 10th 2019
Immutep Announces Upcoming Industry Conference Participation
April 30th 2019
Operational Update
March 27th 2019
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
March 25th 2019
Presentation related to webcast 25. March 2019 - Immutep to Present IMP761 Preclinical Results
March 21st 2019
Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
March 18th 2019
Immutep to Present IMP761 Preclinical Results in Global Webcast
March 7th 2019
Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
March 7th 2019
Immutep receives A$872,351 R&D Tax Incentive
March 6th 2019
Immutep doses First Patient in TACTI-002 Phase II Trial
March 5th 2019
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
March 4th 2019
Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
February 26th 2019
Immutep to Present at Upcoming Industry Conferences
January 7th 2019
Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic
December 19th 2018
Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital
November 29th 2018
Immutep Secures European Patent for Eftilagimod Alpha in Combination with Therapeutic Antibodies for Treating Cancer
November 28th 2018
Immutep Granted European Patent for Eftilagimod Alpha in Combination with a PD-1 or PD-L1 Inhibitor
November 27th 2018
New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit
November 16th 2018
Annual General Meeting CEO Presentation
November 16th 2018
Chairman’s Address 2018 Annual General Meeting
November 16th 2018
Results of Annual General Meeting
November 12th 2018
Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
November 1st 2018
Operational Update
October 24th 2018
Immutep Announces Data Presentations at Upcoming Industry Conferences
October 12th 2018
Notice of Annual General Meeting/Proxy Form
October 2nd 2018
Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
September 26th 2018
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
September 24th 2018
Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
September 3rd 2018
Progress Towards Clinical Development of IMP761 - A LAG-3 Agonist Antibody
August 21st 2018
Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government
August 16th 2018
Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference
August 7th 2018
Immutep Secures Canadian Patent Grant for IMP731 Antibody
August 7th 2018
TACTI-mel Patient Recruitment Complete and Operational Update
July 31st 2018
Immutep's LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA
July 2nd 2018
Immutep Submits Investigational New Drug (IND) Application with FDA
June 19th 2018
Mid-Point of Patient Enrolment Reached in AIPAC Trial
June 4th 2018
Immutep Presentations at ASCO
May 30th 2018
Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast
May 17th 2018
Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
May 4th 2018
Immutep to Present at 2018 ASCO Annual Meeting
April 13th 2018
Immutep Completes $6.31 Million Share Purchase Plan; Raises Total of $13.16 Million
April 3rd 2018
Operational Update
March 22nd 2018
Updated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
March 22nd 2018
Immutep Commences Patient Dosing In Additional TACTI-mel Cohort
March 13th 2018
Share Purchase Plan Offer Document
March 12th 2018
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement with MSD
March 11th 2018
Immutep Raises A$6.85M Through Institutional Placement
March 6th 2018
Immutep Announces United States Patent Grant for IMP701 Antibody
March 5th 2018
Immutep receives A$686,704 R&D Tax Incentive
February 9th 2018
Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial
February 1st 2018
Immutep Limited Announces Milestone Payment from Chinese Partner EOC Pharma
December 12th 2017
Operational Update
November 28th 2017
Prima BioMed Becomes Immutep
November 22nd 2017
Prima Secures European Patent Grant for Lead Product IMP321 in Cancer
November 20th 2017
Prima BioMed Changes its Name to Immutep Ltd
November 20th 2017
FAQ - Change of company name from 'Prima BioMed Limited' to 'Immutep Limited'
November 17th 2017
Chairman’s Address 2017 Annual General Meeting
November 17th 2017
Results of Annual General Meeting
November 17th 2017
Annual General Meeting CEO Presentation
November 15th 2017
Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA
November 9th 2017
New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
November 1st 2017
Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
October 20th 2017
Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017
October 17th 2017
Notice of Annual General Meeting/Proxy Form
October 17th 2017
IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
September 8th 2017
Prima Secures Japanese Patent Grant for IMP731 Antibody
September 5th 2017
Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease
August 30th 2017
Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project
August 21st 2017
Prima BioMed Appoints Non-Executive Director to the Board
August 21st 2017
Appendix 3X
August 7th 2017
Appendix 3B
August 7th 2017
Appendix 3Y
August 6th 2017
Prima BioMed Receives A$1.3 Million Tax Refund from French Government
July 18th 2017
Financial Update 2H17
July 17th 2017
Prima BioMed Announces Second Milestone Payment for IMP701 Program
July 10th 2017
Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial
July 6th 2017
Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)
July 6th 2017
Cleansing Notice
July 4th 2017
Appendix 3B – US$5m Capital Raising
July 3rd 2017
Final Prospectus Supplement
June 30th 2017
Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares
June 26th 2017
Operational Update
June 5th 2017
LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial
June 5th 2017
ASCO Poster 2017
June 1st 2017
Prima BioMed Announces Formation of Clinical Advisory Board
May 18th 2017
Data from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference
April 19th 2017
Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial
April 12th 2017
Prima BioMed receives A$492,144 Tax Refund from Australian Government
March 15th 2017
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
March 1st 2017
USA Patent Grants for IMP321 in Cancer
February 24th 2017
First Half 2017 Operational Update
February 13th 2017
Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government
January 23rd 2017
Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference
January 20th 2017
Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer
January 18th 2017
Prima BioMed to Maintain NASDAQ Listing
January 12th 2017
Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
January 5th 2017
Prima BioMed enters new Material Transfer Agreement with Cytlimic
January 2nd 2017
Prima announces new Product Candidate IMP761 – a LAG-3 Agonist Antibody
December 29th 2016
PRIMA BIOMED ANNOUNCES FIRST CLINICAL DATA FROM COMBINATION OF IMP321 WITH ANTI-PD1
December 22nd 2016
PRIMA BIOMED ANNOUNCES DATA FROM IMP321 AIPAC CLINICAL TRIAL IN BREAST CANCER
December 5th 2016
PRIMA BIOMED ENTERS INTO SALE AND LICENSING AGREEMENT WITH SYDYS TO ADVANCE CVAC™ PROGRAM
October 13th 2016
PRIMA TO PRESENT AT 2016 SOCIETY FOR IMMUNOTHERAPY OF CANCER CONFERENCE
October 6th 2016
PRIMA ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT ESMO SYMPOSIUM ON IMMUNO-ONCOLOGY
August 18th 2016
Operational Update
August 10th 2016
PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY
July 12th 2016
PRIMA BIOMED COLLABORATES IN INVESTIGATOR SPONSORED NEW CLINICAL TRIAL FOR IMP321 IN SOLID TUMORS
July 6th 2016
PRIMA BIOMED TO MAINTAIN NASDAQ LISTING
June 22nd 2016
PRIMA BIOMED ANNOUNCES FIRST SAFETY, PHARMACOKINETICS AND IMMUNO-MONITORING DATA FROM PHASE IIB CLINICAL TRIAL OF IMP321
March 15th 2016
IMP321 SAFETY AND IMMUNE MONITORING DATA PUBLISHED IN CLINICAL CANCER RESEARCH JOURNAL
March 4th 2016
PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY
March 2nd 2016
Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial
February 5th 2016
JAPANESE PATENT GRANTS FOR IMP321 IN CANCER
January 28th 2016
US PATENT GRANTS FOR IMP731 ANTIBODY
January 27th 2016
PRIMA BIOMED INITIATES PHASE I MELANOMA STUDY IN AUSTRALIA
December 22nd 2015
PRIMA BIOMED INITIATES PHASE IIB STUDY IN METASTATIC BREAST CANCER
December 11th 2015
PRIMA BIOMED PROGRESSES JAPANESE COLLABORATION
November 26th 2015
PRIMA BIOMED RECEIVES TAX REBATE FROM AUSTRALIAN GOVERNMENT
November 18th 2015
PRIMA BIOMED UNVEILS PHASE I COMBINATION STUDY OF IMP321 + CHECKPOINT INHIBITOR
November 5th 2015
PRIMA BIOMED WILL PRESENT AT THE ICI EUROPE MEETING IN GERMANY, NOVEMBER 16-18, 2015
October 27th 2015
PRIMA BIOMED GAINS BELGIAN REGULATORY APPROVAL TO COMMENCE A REGISTRATION PHASE IIB STUDY OF IMP321
October 13th 2015
PRIMA BIOMED RAISES A$1.55M THROUGH PLACEMENT TO SOPHISTICATED EUROPEAN HEALTHCARE INVESTOR
October 9th 2015
PRIMA BIOMED RECEIVES GRANT FROM THE SAXONY DEVELOPMENT BANK
September 25th 2015
PRIMA BIOMED TO PRESENT AT LEERINK PARTNERS RARE DISEASE ROUNDTABLE
August 14th 2015
PRIMA BIOMED ANNOUNCES COMMENCEMENT OF MILESTONES FOR IMP701 PROGRAM
August 4th 2015
PRIMA BIOMED TERMINATES INVESTMENT FACILITY WITH BERGEN GLOBAL OPPORTUNITY FUND, LP
August 1st 2015
Re: Results of 2015 Extraordinary General Meeting
July 31st 2015
Prima Biomed Ltd 2015 Extraordinary General Meeting
July 24th 2015
PRIMA BIOMED RAISES A$10M THROUGH SHARE PURCHASE PLAN
July 10th 2015
SHARE PURCHASE PLAN OFFER DOCUMENTS
July 7th 2015
PRIMA BIOMED RECEIVES POSITIVE SCIENTIFIC ADVICE FROM THE EUROPEAN MEDICINES AGENCY FOR ITS LEAD PRODUCT, IMP321
June 29th 2015
A MESSAGE FROM THE CHAIRMAN
June 11th 2015
PRIMA BIOMED RECEIVES A RESEARCH TAX CREDIT CASH REBATE IN FRANCE
June 4th 2015
PRIMA BIOMED TO MAINTAIN NASDAQ LISTING
May 29th 2015
PRIMA BIOMED ANNOUNCES NEW IP FOR ITS LEAD IMP321 DEVELOPMENT PROGRAM
May 25th 2015
PRIMA BIOMED TO COMMERCIALISE CVAC’S DATABASE MANAGEMENT PLATFORM WITH DATABASE INTEGRATIONS INC. (DBI)
May 19th 2015
CVAC SHOWS OVERALL SURVIVAL BENEFIT IN SECOND REMISSION OVARIAN CANCER IN PHASE II STUDY
May 14th 2015
PRIMA BIOMED ANNOUNCES A$15 MILLION INVESTMENT FROM US HEALTHCARE INVESTOR RIDGEBACK
May 11th 2015
PRIMA BIOMED ANNOUNCES JAPANESE COLLABORATION
April 29th 2015
PRIMA BIOMED TO PRESENT AT CANARY NETWORKS’ BIOTECH AND HEALTHCARE INVESTOR ROADSHOW
February 27th 2015
PRIMA BIOMED PRIORITISING IMP321
January 27th 2015
FINANCIAL MILESTONE PAYMENT TO BE RECEIVED FROM GSK
January 20th 2015
$777K R&D TAX INCENTIVE REFUND RECEIVED
January 20th 2015
PRIMA BIOMED APPOINTS GLOBAL HEAD OF INVESTOR RELATIONS
We use cookies and other tracking technologies to improve your browsing experience on our website, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies. To learn more about cookies view ourPrivacy policy
